Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.79 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | BRD4 | O60885 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | LTA4H | P09960 | 1/20 | 0.79 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669511 | 0.96 | HDAC4 (0.85) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL137348 | 0.96 | HDAC4 (0.85) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL6665592 | 0.96 | HDAC4 (0.85) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL1065393 | 0.96 | HDAC4 (0.85) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL517309 | 0.94 | HDAC4 (0.81) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL1065527 | 0.92 | HDAC6 (0.74) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL1433994 | 0.92 | HDAC6 (0.74) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL14135053 | 0.91 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL31203555 | 0.91 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL28608420 | 0.91 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC7HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178290-A9 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4359570-A1 | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER | Foundation Medicine, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240093304-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4337795-A2 | CD274 MUTATIONS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024007015-A2 | RET GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230416831-A1 | COMPREHENSIVE GENOMIC PROFILING (CGP) OF METASTATIC INVASIVE LOBULAR CARCINOMAS REVEALS HETEROGENEITY | FOUNDATION MEDICINE, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023235822-A1 | IGF1R ACTIVATION MUTATIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022125470-A1 | COMPREHENSIVE GENOMIC PROFILING (CGP) OF METASTATIC INVASIVE LOBULAR CARCINOMAS REVEALS HETEROGENEITY | FOUNDATION MEDICINE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2021178595-A2 | BCOR REARRANGEMENTS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210121511-A1 | VIRUS-LIKE PARTICLE COMPOSITIONS AND METHODS OF USING SAME | UNM RAINFOREST INNOVATIONS | 2021-04-29 | — | — | US | disclosed |
| US-9579346-B2 | Treatment of macrophage-related disorders | THE REGENTS OF THE UNIVERITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2016081281-A1 | LIPOPHILIC BISPHOSPHONATES AND METHODS OF USE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20150037320-A1 | TREATMENT OF MACROPHAGE-RELATED DISORDERS | NEURALTUS PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2461694-A2 | TREATMENT OF MACROPHAGE-RELATED DISORDERS | Neuraltus Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120134929-A1 | TREATMENT OF MACROPHAGE-RELATED DISORDERS | NEUVIVA, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2011017030-A2 | TREATMENT OF MACROPHAGE-RELATED DISORDERS | NEURALTUS PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |